Asia’s Most Promising Brands 2017 – Beximco Pharmaceuticals Ltd
[/et_pb_text][et_pb_image src=”https://mostadmiredasia.com/wp-content/uploads/2017/11/BEXIMCO-PHARMA-1.jpg” alt=”Asia’s Most Promising Brands 2017 – Beximco Pharmaceuticals Ltd” title_text=”Asia’s Most Promising Brands 2017 – Beximco Pharmaceuticals Ltd” url=”http://mostadmiredasia.com/asias-most-promising-brands-2017″ url_new_window=”on” align=”center” _builder_version=”3.0.89″ max_width=”34%” /][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”3.0.87″][et_pb_column type=”4_4″][et_pb_image src=”http://mostadmiredasia.com/wp-content/uploads/2017/11/BEXIMCO-PHARMA.jpg” alt=”Asia’s Most Promising Brands 2017 – Beximco Pharmaceuticals Ltd” title_text=”Asia’s Most Promising Brands 2017 – Beximco Pharmaceuticals Ltd” url=”http://www.beximco-pharma.com/” url_new_window=”on” _builder_version=”3.0.89″ /][et_pb_blurb title=”THE MEDICAL MARVEL FOR CURE” url=”http://mostadmiredasia.com/asias-promising-brands-2017/” url_new_window=”on” disabled_on=”off|off|off” _builder_version=”3.0.89″ header_font=”||||||||” header_text_align=”center” header_font_size=”50px” header_font_size_last_edited=”on|desktop”]With a global footprint in more than 50 countries and counting, Beximco Pharmaceuticals Ltd. is now hailed as the largest exporter of medicines in Bangladesh. The flagship company of the Beximco Group, which is the largest private sector industrial conglomerate in the country, Beximco Pharmaceuticals specializes in the manufacturing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients (APIs). Enduring decades of contract manufacturing with global MNCs, Beximco Pharmaceuticals continues to build visibility and eminent presence across continents and has been offering distinct, supreme quality and affordable generics since 1976.
The company’s first foray into operations was under a licensing agreements with Bayer AG (Germany) and Upjohn Inc. (USA) for manufacturing and arketing in 1980. It did not take long for the company to commence manufacturing of its own formulations in 1983 and subsequently embark upon its first export operations in 1992. Today, the Beximco Pharmaceuticals portfolio embodies a collective of therapeutically scientific areas of medicine – Analgesics, Antibiotics, Cardiovascular, Central Nervous System, Dermatology, Gastroenterology, Anti-Diabetics and Respiratory, among others.
Yet Beximco Pharmaceuticals is continuing to further enhance its portfolio from its current production line of over 500 products in various dosage forms mentioned afore. The company’s state-of-the-art manufacturing facilities have been built in compliance with the US FDA and EU GMP standards. Beximco Pharmaceuticals has had the honour of being the only pharmaceutical company in the country to win the National Export Trophy (Gold) for a record four times; this decorated accolade is regarded as the foremost and highest commendation which accedes significant contribution to the country’s economic welfare in the export sector. Unequivocally speaking, Beximco Pharmaceuticals possesses the highest number of international accreditations in the country in the pharma sector.
Beximco Pharmaceuticals has been acclaimed for securing the highest number of GMP (Good Manufacturing Practice) accreditations which include Agency for Health & Food Safety (AGES) Austria, Therapeutic Goods Administration (TGA) Australia, Gulf Central Committee (GCC Member States), ANVISA Brazil, INVIMA Colombia, and MCC South Africa. Since the company’s inception, Beximco Pharmaceuticals has ascertained itself as a conscientious partner for a large number of pharmaceutical companies across the globe by adhering to international standards and by providing a work culture reminiscent of those of a multi-national corporation. In an industry facing rising costs in healthcare & medicine, there is a growing concern to reduce costs across value chains, ergo, the pharmaceutical corporations from developed markets strive to identify cohesive partnerships in developing nations to outsource production and marketing. Beximco Pharmaceutical’s generics have been well acknowledged and received in international markets; some of the eminent and reputed companies and institutions that affiliate with the brand’s generic product line are – Raffles Hospital, Heathway and KK Women’s & Children’s Hospital from Singapore, MEDS and Kenyatta National Hospital in Kenya and many more. Beximco Pharmaceuticals has also been entrusted as a supplier for UNICEF (United Nations Children’s Fund), Save the Children, WHO (World Health Organization), and ADF (Asthma Drug Facility). Beximco Pharmaceuticals has become the first pharma company in the country to enter Europe with its sterile ophthalmics range while it already made forays into the US pharma market in 2011, which was again a milestone achievement for the country’s pharma industry.
Whilst creating economic values in the community of operation, the social value aspect does emphasize a need for the hour, following the company’s guiding principles ‘to make significant contribution to humanity by improving health’; engaging responsibily towards the welfare of the community at large guides the company’s operations – to be a trusted partner in health –to work closely with non-profit organizations that function for the improvisation of people’s lives through research, information, and advocacy. Beximco Pharmaceuticals has joined hands with USAID-led ‘Mobile Alliance for Maternal Action (MAMA) – an innovative initiative to communicate or provide health messages to pregnant women and new mothers linked to
their delivery date through mobile phone. The purpose of this service is also to educate the family gatekeepers who aspire to seek and learn healthcare related facts and behaviors under the brand name ‘Aponjon’. To engage and address issues concerning asthma, diabetes, hypertension and more, Beximco Pharmaceuticals has initiated campaign activities, rallies, scientific seminars, and conferences with multifarious associations and societies in the medical field alongside starting employee volunteering program to encourage children’s survival against cancer clubbed along with donations to palliative care units for those suffering from terminal cancer. The company has collaborations with globally renowned biotech companies and has also provided free technical support to vaccine studies conducted by Johns Hopkins University. Beximco Pharmaceuticals remains committed to protecting the environment by reducing its’ carbon footprint and promoting eco-friendly operations and business practices. They were among the first few in the world who proactively made the transition away from ozone depleting CFC based inhaler formulations to the eco friendly HFA version.
Behind every pharmaceutical company is a formidable Research & Development capability. With a team of top analytical scientists, Beximco Pharmaceuticals strives to integrate the advancements in technological changes to match international standards. The world has witnessed its success in generic drug manufacturing capabilities and successful development of difficult formulations of drugs such as multi-layered tablets, dispersible tablets, sustained release tablets, CFC-free inhalers, and more coupled with dosage delivery products driven by technological advancements for prefilled syringes, total parenteral nutrition, dry powder inhalers, sterile ophthalmics and lyophilized products. A homegrown state-of-theart manufacturing facility – which extends over 23 acres – has been developed for the production of all drugs and dosage delivery systems with its own utility infrastructure along with water purification and liquid nitrogen facilities.
After decades of contract manufacturing experience with global MNCs, skilled manpower and proven formulation capabilities, the company offers high quality generics at the most affordable cost, thereby ensuring access to quality medicines for the betterment of healthcare for mankind.
Power FACTS
Beximco Pharmaceuticals is the only Bangladeshi company to get listed on the AIM of London Stock Exchange.
Beximco Pharmaceuticals is the largest producer of metered dose inhalers (MDIs) and other specialty drugs in the country. They currently produce more than 300 generics in over 500 different strengths and dosage forms.
Their pool of selected customers includes globally reputed hospitals and institutes. They have become the first pharma company in the country to enter the US and EU market and have a sound track record of working with global MNCs.
[/et_pb_blurb][/et_pb_column][/et_pb_row][/et_pb_section]
